X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
oncology (9) 9
hematology (8) 8
index medicus (8) 8
multiple myeloma (7) 7
multiple myeloma - drug therapy (7) 7
hematology, oncology and palliative medicine (4) 4
apoptosis (3) 3
apoptosis - drug effects (3) 3
article (3) 3
bone marrow (3) 3
bortezomib (3) 3
cell proliferation - drug effects (3) 3
female (3) 3
genetic aspects (3) 3
survival (3) 3
animals (2) 2
antigen-presenting cells (2) 2
bone marrow cells - drug effects (2) 2
cancer (2) 2
gene-expression (2) 2
growth (2) 2
health aspects (2) 2
histone deacetylase inhibitor (2) 2
histone deacetylase inhibitors (2) 2
hydroxamic acids - administration & dosage (2) 2
intergroupe francophone (2) 2
lenalidomide (2) 2
mice (2) 2
minimal residual disease (2) 2
multiple myeloma - genetics (2) 2
multiple myeloma - pathology (2) 2
multiple-myeloma (2) 2
oxidative stress (2) 2
patient outcomes (2) 2
positron-emission-tomography (2) 2
proteins (2) 2
risk factors (2) 2
stem-cell transplantation (2) 2
thalidomide - analogs & derivatives (2) 2
thalidomide - therapeutic use (2) 2
therapy (2) 2
urine (2) 2
usage (2) 2
working groups (2) 2
3 aminothalidomide (1) 1
actins - genetics (1) 1
adjuvants, immunologic - therapeutic use (1) 1
adrenal cortex hormones - pharmacology (1) 1
adult (1) 1
aged (1) 1
aged, 80 and over (1) 1
analogs (1) 1
analysis (1) 1
angiogenesis inhibitors - pharmacology (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
anthelmintics - pharmacology (1) 1
anti-infective agents - pharmacology (1) 1
anti-myeloma (1) 1
antibody daratumumab (1) 1
anticancer agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - isolation & purification (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - pharmacology (1) 1
apoptosis - genetics (1) 1
apoptosis regulatory proteins - metabolism (1) 1
b ligand rankl (1) 1
b-lymphocytes - drug effects (1) 1
b-lymphocytes - secretion (1) 1
bcl-2-like protein 11 (1) 1
binding proteins (1) 1
biochemistry & molecular biology (1) 1
biological evaluation (1) 1
biological markers (1) 1
biological response modifiers (1) 1
biomakers (1) 1
biopsy (1) 1
bmt (1) 1
bone diseases (1) 1
bone marrow cells - cytology (1) 1
bone marrow transplantation - adverse effects (1) 1
bone-lesions (1) 1
bone-marrow (1) 1
bone-marrow angiogenesis (1) 1
bone-marrow-transplantation (1) 1
boronic acids - administration & dosage (1) 1
boronic acids - pharmacology (1) 1
breast-cancer (1) 1
cannabinoid receptor agonists - pharmacology (1) 1
cannabinoid receptor-2 (1) 1
cannabinoid receptor‐2 (1) 1
carboxy-terminal telopeptide (1) 1
cardiac glycosides - pharmacology (1) 1
care and treatment (1) 1
caspases - genetics (1) 1
cb2 receptor (1) 1
cdc2 protein kinase - genetics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Journal Article
Molecular Carcinogenesis, ISSN 0899-1987, 12/2015, Volume 54, Issue 12, pp. 1796 - 1806
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2007, Volume 139, Issue 3, pp. 385 - 397
Summary Clinical trials have shown the high anti-myeloma activity of the proteasome inhibitor bortezomib. The present study examined the activity of bortezomib... 
apoptosis | multiple myeloma | osteoclastogenesis | PXD101 | oxidative stress | Osteoclastogenesis | Oxidative stress | Multiple myeloma | Apoptosis | MECHANISM | INDUCED APOPTOSIS | TRIGGERS | CELL LUNG-CANCER | OSTEOCLAST FORMATION | GROWTH | GENERATION | PROTEASOME INHIBITOR | HEMATOLOGY | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Pyrazines - administration & dosage | Neoplasm Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Bcl-2-Like Protein 11 | Hydroxamic Acids - administration & dosage | Bone Marrow Cells - drug effects | Membrane Proteins - metabolism | Boronic Acids - administration & dosage | Drug Evaluation, Preclinical | Hydroxamic Acids - pharmacology | Proto-Oncogene Proteins - metabolism | Cell Survival - drug effects | Bortezomib | Osteogenesis - drug effects | Enzyme Inhibitors - pharmacology | Multiple Myeloma - metabolism | Apoptosis Regulatory Proteins - metabolism | Drug Synergism | Multiple Myeloma - pathology | Sulfonamides | Cell Line, Tumor | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors | DNA Damage | DNA, Neoplasm - genetics | Oxidative Stress - drug effects | Pyrazines - pharmacology | Multiple Myeloma - genetics | Boronic Acids - pharmacology | Genetic research | Genetic aspects | DNA | Cancer
Journal Article
Experimental Hematology, ISSN 0301-472X, 2006, Volume 34, Issue 6, pp. 776 - 787
Histone deacetylase (HDAC) inhibitors reduce development of graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (BMT).... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | INTERFERON-GAMMA | REVERSIBLE ACETYLATION | BONE-MARROW-TRANSPLANTATION | GENE-EXPRESSION | ANTIGEN-PRESENTING CELLS | RENAL-DISEASE | TNF-ALPHA | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | T-LYMPHOCYTES | Phosphorylation | Transplantation, Homologous | Enzyme Inhibitors - administration & dosage | STAT1 Transcription Factor - metabolism | Protein Processing, Post-Translational - drug effects | T-Lymphocytes - metabolism | Hydroxamic Acids - administration & dosage | Female | Graft vs Host Disease - etiology | STAT3 Transcription Factor - metabolism | Cytokines - metabolism | Liver - metabolism | Histone Deacetylases - metabolism | STAT1 Transcription Factor - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Spleen - metabolism | Lymphocyte Activation - drug effects | Lipopolysaccharides - pharmacology | Bone Marrow Transplantation - adverse effects | Graft vs Host Disease - prevention & control | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors | Inflammation - prevention & control | Mice | Mice, Inbred BALB C | Histocompatibility | Inflammation - enzymology | Graft vs Host Disease - enzymology | Bone marrow | Transplantation | Universities and colleges | T cells | Biological response modifiers | Mitogens | Interferon gamma
Journal Article
Journal Article